Meta-analysis finds ketamine shows no significant pain benefit for acute bone fractures in adultsKetamine Does Not Reduce Pain in Broken Bones

This systematic review and meta-analysis examined the efficacy of ketamine for pain management in adult patients with acute bone fractures. The analysis included 1,453 patients across multiple studies, though the specific clinical settings were not reported. The population consisted exclusively of adults with acute bone fractures, with no further demographic details provided. The study represents Level III evidence according to the authors' classification.

The intervention evaluated was ketamine administration, either as monotherapy or as an adjuvant to other pain management strategies. The comparator groups received placebo, standard care, or alternative pain management approaches. Specific dosing regimens, routes of administration, and treatment protocols were not detailed in the available data.

For primary outcomes, the meta-analysis found no statistically significant differences in pain intensity between ketamine and comparator groups at multiple time points. At 15 minutes post-administration, there was no significant difference (p>0.05). Similarly, at 30 minutes (p>0.05) and 60 minutes (p>0.05), no statistically significant differences were observed. Effect sizes and absolute numbers for these comparisons were not reported.

Key secondary outcomes also showed no significant differences between groups. Additional analgesia requirements showed no significant difference (p>0.05). Hospital length of stay demonstrated no significant difference (p>0.05). Patient satisfaction scores showed no significant difference (p>0.05). All secondary outcome comparisons lacked reported effect sizes and absolute numbers.

Safety findings revealed important considerations. Overall adverse event rates were comparable between ketamine and comparator groups. However, ketamine was associated with substantially increased rates of specific adverse events: nervous system adverse events occurred in 48% of ketamine patients versus 16% of comparator patients, and psychiatric adverse events occurred in 14.6% of ketamine patients versus 4% of comparator patients. Serious adverse events, discontinuation rates, and overall tolerability were not reported.

When compared to prior research on acute pain management, these findings contrast with some studies suggesting ketamine's potential utility in specific acute pain scenarios. The negative primary results align with concerns about ketamine's side effect profile relative to its analgesic benefits in non-operative settings. The sensitivity analysis findings (discussed below) create some tension with the overall negative results, suggesting methodological factors may influence conclusions.

Methodological limitations are significant. The authors classify this as Level III evidence, indicating inherent limitations in the quality of included studies. The sensitivity analysis revealed important nuances: when excluding studies with high risk of bias, pain intensity at 30 minutes showed significant improvement with ketamine (SMD -0.43, 95% CI -0.12 to 0.75, p=0.007). At 15 minutes with the same exclusion, there was a trend toward improved ketamine efficacy (SMD -1.24, 95% CI -2.72 to 0.24, p=0.10). These sensitivity results suggest that study quality substantially impacts conclusions about ketamine's efficacy.

Clinical implications are nuanced. For most clinicians managing acute bone fractures, current evidence does not support routine ketamine use given the lack of significant pain benefit in the primary analysis and the increased risk of nervous system and psychiatric adverse events. However, the sensitivity analysis suggests that in higher-quality studies, ketamine may show benefit at specific time points, particularly 30 minutes post-administration. This creates a complex risk-benefit calculation where ketamine's potential modest analgesic benefit must be weighed against its substantial side effect profile.

Several important questions remain unanswered. Optimal dosing regimens and routes of administration for ketamine in fracture pain were not elucidated. The specific fracture types that might respond differently to ketamine were not analyzed separately. Long-term outcomes beyond 60 minutes were not assessed. Patient subgroups that might derive particular benefit or harm from ketamine were not identified. The comparative efficacy against specific alternative analgesics (rather than the heterogeneous comparator group used) remains unclear. These gaps highlight the need for higher-quality randomized controlled trials with standardized protocols and longer follow-up periods.